CN105120892B - 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物 - Google Patents

包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物 Download PDF

Info

Publication number
CN105120892B
CN105120892B CN201380073503.5A CN201380073503A CN105120892B CN 105120892 B CN105120892 B CN 105120892B CN 201380073503 A CN201380073503 A CN 201380073503A CN 105120892 B CN105120892 B CN 105120892B
Authority
CN
China
Prior art keywords
cdtb
protein
cdta
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380073503.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105120892A (zh
Inventor
C.卡斯塔多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN105120892A publication Critical patent/CN105120892A/zh
Application granted granted Critical
Publication of CN105120892B publication Critical patent/CN105120892B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380073503.5A 2012-12-23 2013-12-20 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物 Active CN105120892B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1223342.5A GB201223342D0 (en) 2012-12-23 2012-12-23 Immunogenic composition
GB1223342.5 2012-12-23
PCT/EP2013/077762 WO2014096393A1 (en) 2012-12-23 2013-12-20 Immunogenic composition comprising elements of c. difficile cdtb and/or cdta proteins

Publications (2)

Publication Number Publication Date
CN105120892A CN105120892A (zh) 2015-12-02
CN105120892B true CN105120892B (zh) 2020-07-31

Family

ID=47682553

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380073503.5A Active CN105120892B (zh) 2012-12-23 2013-12-20 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物

Country Status (12)

Country Link
US (2) US9669083B2 (https=)
EP (1) EP2934579B1 (https=)
JP (1) JP6515036B2 (https=)
CN (1) CN105120892B (https=)
AR (1) AR094275A1 (https=)
AU (1) AU2013366450A1 (https=)
BR (1) BR112015014727B8 (https=)
CA (1) CA2894951C (https=)
ES (1) ES2748054T3 (https=)
GB (1) GB201223342D0 (https=)
SG (1) SG11201504701UA (https=)
WO (1) WO2014096393A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2753352T5 (pl) 2010-09-03 2022-10-17 Valneva Austria Gmbh Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
TWI815599B (zh) 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
WO2013084071A2 (en) * 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
BE1022949B1 (fr) * 2014-06-25 2016-10-21 Glaxosmithkline Biologicals S.A. Composition immunogene
MX2019010948A (es) * 2017-03-15 2020-01-09 Novavax Inc Métodos y composiciones para inducir respuestas inmunitarias contra clostridium difficile.
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
US12076352B2 (en) 2018-06-19 2024-09-03 Glaxosmithkline Biologicals Sa Immunogenic composition
CN111793130B (zh) * 2019-03-20 2021-09-14 华中农业大学 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用
WO2021022033A1 (en) 2019-07-30 2021-02-04 Leung Kai P Layered composite for scar treatment and prevention
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2025029561A2 (en) * 2023-07-28 2025-02-06 University Of South Florida Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104039816A (zh) * 2012-01-27 2014-09-10 默沙东公司 包含重组毒素的针对艰难梭菌的疫苗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2656850T3 (es) * 2009-02-11 2018-02-28 Cedars-Sinai Medical Center Diagnóstico del síndrome intestinal inflamatorio con base en la toxina de distensión citoletal
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
PL2753352T5 (pl) * 2010-09-03 2022-10-17 Valneva Austria Gmbh Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104039816A (zh) * 2012-01-27 2014-09-10 默沙东公司 包含重组毒素的针对艰难梭菌的疫苗

Also Published As

Publication number Publication date
US9669083B2 (en) 2017-06-06
JP6515036B2 (ja) 2019-05-15
GB201223342D0 (en) 2013-02-06
US20180043005A1 (en) 2018-02-15
BR112015014727B1 (pt) 2022-08-02
BR112015014727B8 (pt) 2022-09-20
CN105120892A (zh) 2015-12-02
CA2894951C (en) 2023-05-09
AR094275A1 (es) 2015-07-22
AU2013366450A1 (en) 2015-07-23
SG11201504701UA (en) 2015-07-30
BR112015014727A2 (pt) 2017-10-10
JP2016504993A (ja) 2016-02-18
EP2934579A1 (en) 2015-10-28
EP2934579B1 (en) 2019-08-07
US20150313985A1 (en) 2015-11-05
CA2894951A1 (en) 2014-06-26
ES2748054T3 (es) 2020-03-12
WO2014096393A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
CN105120892B (zh) 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物
JP6626521B2 (ja) 免疫原性組成物
JP5922074B2 (ja) 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ）ポリペプチドおよびその融合物を含む免疫原性組成物
WO2007079684A1 (fr) Proteines de fusion de mycobacterium tuberculosis et utilisations
ES2728865T3 (es) Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
BR112019004913B1 (pt) Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
JP2020100625A (ja) クロストリジウム・ディフィシル免疫原性組成物
JP2015528457A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
JP2015515276A (ja) ヘパリン結合性赤血球凝集素（ｈｂｈａ）融合タンパク質とその用途をコードする組換え型マイコバクテリウム
CA2952118C (en) Clostridium difficile immunogenic composition
JP2015532594A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
JP2018134074A (ja) ヘパリン結合性赤血球凝集素（ｈｂｈａ）融合タンパク質とその用途をコードする組換え型マイコバクテリウム

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant